Table 5.
Sensitivity Study for ERBB2 Amplification Detection
| Sample | Dilution (%) | ERBB2 fold change | Result |
|---|---|---|---|
| FFPE (HER2/CEP17, 13.7) | 100 | 49.38 | AMP called |
| 50 | 14.44 | AMP called | |
| 25 | 6.90 | AMP called | |
| 12.50 | 3.73 | AMP called | |
| 6.25 | 2.34 | AMP called | |
| 3.13 | 1.56 | AMP called | |
| MDA-MB-361 (HER2/CEP17, 4.2) | 100 | 5.66 | AMP called |
| 50 | 3.32 | AMP called | |
| 25 | 2.16 | AMP called | |
| 12.50 | 1.61 | AMP called | |
| 6.25 | 1.33 | AMP not called | |
| MDA-MB-453 (HER2/CEP17, 2.4) | 100 | 2.31 | AMP called |
| 50 | 1.61 | AMP called | |
| 25 | 1.3 | AMP not called | |
| 12.50 | 1.15 | AMP not called | |
| 6.25 | 1.0 | AMP not called |
AMP, amplification; CEP17, chromosome 17 centromere marker; FFPE, formalin-fixed, paraffin-embedded; HER2, human epidermal growth factor receptor 2.